



ASX and MEDIA Announcement

MEDLAB receives UK Import Certificate from UK Home Office for NanaBis™

Sydney, January 25, 2023 - Medlab Clinical Ltd (ASX:MDC) (Medlab, the Company), an Australian biotech using delivery technology to enhance medicines effectiveness, is pleased to announce NanaBis™ (named NanaDol™ for UK purposes) has been issued import certification by the UK Home Office.

Further to the 25 Nov 2022 announcement, the Company has received the import certificate by the UK Home Office and is today applying for export certification from Canberra a process that can take 28 days allowing for the lawful shipment of NanaDol to the UK to be used in the Named Patient Program as outlined by the MHRA and serviced via our partner WEP.

Beyond this the NanaDol™ shipment is ready to move.

Dr Sean Hall CEO of Medlab said, "it's great to be able to expand the successes we have had with NanaBis (named NanaDol for export purposes) to the UK people. As we recently announced, those data points across 1,100 Australian patients were very encouraging. We are looking forward to replicating those success stories."

About NanaBis™

NanaBis™ is being developed for cancer bone pain as this is a population with need of better pain management and is a relatively homogeneous cancer population that provides important characteristics conducive to successful new drug registration and commercialisation. Furthermore, extensive independent preclinical research has identified the active components of NanaBis™, THC and CBD, as being particularly effective for treating cancer bone pain and a published clinical trial carried out by Professor Stephen Clarke at RNSH showed that Bone Cancer pain patients received a strongly clinically significant (40%) reduction in pain from NanaBis™.

About UK

UK is a NanaBis™ clinical trial territory and obtaining Market Authority for NanaBis™ in the UK is a priority. Pre-Market Authority sales of NanaBis™ not only helps patients suffering from chronic pain unsatisfactorily treated by current options, but also provides the UK regulatory bodies (such as the MHRA) with Real World Data on the safety, tolerability and efficacy of NanaBis™ in UK-specific population and generates patient advocates and key opinion leaders. It will also further demonstrate a real demand for NanaBis™ and provide valuable data to guide our clinical trial program.

- ENDS -

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

About Medlab Clinical:

Medlab Clinical LTD (ASX:MDC) is pioneering the use of NanoCelle® a proprietary, patented delivery technology using water soluble nanoparticles®, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab's investigative drug pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. Patented lead drug candidate NanaBis™ is being developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain. Medlab operates in Australia (Head Office), USA, and the UK.

For more information, please visit www.medlab.co

Medlab – better medicines, better patient care

For further information contact:

Dr. Sean Hall, CEO, Medlab Clinical Ltd

T: +61 411 603 378 | E: sean_hall@medlab.co

Medlab Clinical Limited, Units A5-A6, 11 Lord Street, Botany NSW 2019

P: +61 2 8188 0311 | W: www.medlab.co | ACN: 169 149 071